Lv3
392 积分 2025-01-03 加入
Outcomes After Incomplete N1 Versus N2 Nodal Evaluation in Stage I Non-Small Cell Lung Cancer
6小时前
已关闭
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
17小时前
已完结
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2
5天前
已关闭
An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval
6天前
已完结
2026 Revised Recommendations of The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer
7天前
已完结
Natural history, treatment, survival, and causes of mortality in patients with subsolid and ground-glass nodules
11天前
已完结
Exploring the immunological effects of antibody–drug conjugates
13天前
已完结
High programmed death-ligand 1 expression is associated with a shorter progression free survival in ALK-rearranged lung cancer patients treated with first line tyrosine kinase inhibitors
13天前
已完结
MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC
14天前
已完结
Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights From a Large-Scale Real-World Chinese Cohort
14天前
已完结
皖公网安备34019202002308
